Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | DNMT1 | P26358 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | STAT3 | P40763 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL164192 | 1.00 | KMT2A (1.00) | KMT2ADNMT1CYP2C19DNMT3BPKM | |
| SCHEMBL11949518 | 1.00 | KMT2A (1.00) | KMT2ADNMT1CYP2C19DNMT3BPKM | |
| SCHEMBL30167914 | 1.00 | KMT2A (1.00) | KMT2ADNMT1CYP2C19DNMT3BPKM | |
| SCHEMBL28518031 | 0.90 | DNMT1 (0.81) | KMT2ADNMT1CYP2C19DNMT3BPKM | |
| SCHEMBL5306820 | 0.89 | KMT2A (0.80) | KMT2ADNMT1CYP2C19DNMT3BPKM | |
| SCHEMBL5306824 | 0.89 | KMT2A (0.80) | KMT2ADNMT1CYP2C19DNMT3BPKM | |
| SCHEMBL19244077 | 0.87 | DNMT1 (0.76) | KMT2ADNMT1CYP2C19DNMT3BPKM | |
| SCHEMBL30382095 | 0.87 | DNMT1 (0.76) | KMT2ADNMT1CYP2C19DNMT3BPKM | |
| SCHEMBL21439464 | 0.87 | DNMT1 (0.76) | KMT2ADNMT1CYP2C19DNMT3BPKM | |
| SCHEMBL14174620 | 0.87 | KMT2A (0.77) | KMT2ADNMT1CYP2C19DNMT3BPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119766-A1 | EX VIVO GENERATION OF GAMMA DELTA FOXP3+ REGULATORY T CELLS AND THERAPEUTIC USES THEREOF | UNIVERSITÉ PARIS CITÉ (FR) | 2022-04-21 | — | — | US | claimed |
| US-11198851-B2 | Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereof | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERE MEDICALE) (FR) | 2021-12-14 | — | — | US | claimed |
| CN-113543806-A | Drug delivery combining epigenetic regulation and immune checkpoint blockade | 北卡罗莱纳州立大学 | 2021-10-22 | — | — | CN | claimed |
| US-9896659-B2 | Methods, kits, and compositions for stem cell self-renewal | STOWERS INSTITUTE FOR MEDICAL RESEARCH (US) | 2018-02-20 | — | — | US | claimed |
| US-20140255359-A1 | METHODS, KITS, AND COMPOSITIONS FOR STEM CELL SELF-RENEWAL | STOWERS INSTITUTE FOR MEDICAL RESEARCH | 2014-09-11 | — | — | US | claimed |
| EP-1993553-B1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY SCIENCE TECH & RES (SG) | 2013-05-08 | — | — | EP | claimed |
| US-20100305059-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-12-02 | — | — | US | claimed |
| EP-1993553-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | Agency for Science, Technology and Research (SG) | 2008-11-26 | — | — | EP | claimed |
| WO-2008027049-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | WO | claimed |
| WO-2007100304-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2007-09-07 | — | — | WO | claimed |
| US-20250319183-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | AVIGAN DAVID (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250288687-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATES AND DNMT INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-09-18 | — | — | US | disclosed |
| EP-3878949-B1 | REPROGRAMMING OF SOMATIC CELLS | WHITEHEAD INST BIOMEDICAL RES (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12156856-B2 | Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability | Traws Pharma, Inc. (US) | 2024-12-03 | — | — | US | disclosed |
| CN-118354759-A | Compositions comprising 2' -deoxycytidine analogs and their use for treating sickle cell disease, thalassemia and cancer | 阿基拉比奥有限公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-1993553-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | Agency for Science, Technology and Research (SG) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008124133-A1 | REPROGRAMMING OF SOMATIC CELLS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008027049-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007100304-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007007054-A1 | PHTHALAMIDES, SUCCINIMIDES AND RELATED COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305059-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | DNMT3A, TET2, MCL1 | KMT2A 17/4885DNMT1 4/4885CYP2C19 1924/4885 |
| US-20250319183-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MCL1, BCL2, BCL3 | KMT2A 2681/4885DNMT1 1530/4885CYP2C19 4561/4885 |
| US-20250288687-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATES AND DNMT INHIBITORS | DNMT1, DNMT3B, DNMT3A | KMT2A 40/4885DNMT1 1/4885CYP2C19 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.